Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00088595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
July 31, 2008
Enrollment
45 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumors